Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). “As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning […]
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta®1 100/62.5/25, has been accepted for filing by the […]
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 8:00 am Pacific Time. About Transpire Bio Inc. Transpire Bio Inc. is an integrated, US-based, revenue-generating, […]
Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has successfully dosed the first human subject with its experimental drug candidate in a novel inhalation formulation. The initial clinical study is designed to evaluate pulmonary […]
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
SUNRISE, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a Pre-Approval Inspection (PAI) at its manufacturing facility in Weston, Florida, with a Voluntary Action Indicated (VAI) classification. The company has now […]
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
News US-Based Manufacturing US-Based Manufacturing TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused […]
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
News SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate and vilanterol inhalation powder, a generic version of Breo® Ellipta®1 100/25, has been accepted for filing by the U.S. […]
Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor
News Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor WESTON, Jun 03, 2025 (GLOBE NEWSWIRE) — Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an exclusive license agreement with Suzhou Intragrand […]
Transpire Bio Announces R&D and Manufacturing Expansion
SUNRISE, Fla., May 06, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an agreement to expand the footprint of its R&D and Manufacturing capabilities in Pembroke Pines, Florida. The expansion is expected to enhance and build upon […]
Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
News WESTON, Fla., Jan. 13, 2024 (GLOBE NEWSWIRE) Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the commencement of a new human subject study for its inhalation therapy program targeting asthma and chronic obstructive pulmonary disease (COPD). This advancement builds on the promising results from a previous clinical […]
